Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis
Open accessThe DOI matches its Crossref record.
Abstract
Areport was published in 2003 entitled "Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate."1 Articles appeared in the popular press in 2005 raising concerns about results shown in the two figures in the paper, particularly whether there was a threshold in the relationship between bone turnover markers and vertebral fracture risk and about whether the authors had access to the data.2, 3. The JBMR journal editor and ASBMR chairman of publications requested in December 2005 that a reanalysis be performed that was independent of the sponsoring company. We discussed the need for the independent analysis with Procter & Gamble (P&G), the sponsoring company. We asked for the raw data and proposed that the two authors of the original report used by the company would not be involved in the preparation of this letter. The data were provided to us by P&G in May 2006, together with a report detailing the statistical methodology and the SAS codes used. We confirmed that the bone turnover marker results we had sent the company were the same as those they returned to us. We approached a statistician (MJC) who had no prior collaboration on this project with the original authors and no links to the sponsoring company. Together we conducted a reanalysis of the data. This statistician wrote a report from which we prepared the first draft of this letter. Both documents were sent with the raw data to a second senior medical statistician in August 2006. This independent statistician read through the report, repeated the analyses, and made some valuable comments that were incorporated into this letter. We are attaching as an appendix the checking the original analysis and figures, the description of an alternative approach to the analysis, and the listing the limitations we identified in the original analysis. In this letter, we will address three specific questions with the help of the analysis in the Appendix. In the original paper,1 one of the authors, a statistician working for P&G (IB), had full access to all data. P&G (like most pharmaceutical companies we contacted over this issue) used the PhRMA guidelines in relation to publication of clinical trial data, and these restrict the release of original data to investigators (http://www.phrma.org/). He worked closely with all of the authors of the original report on the data analysis by preparing a publication brief and responded to all requests for further analyses. Thus, the authors had full access to the analyses they had requested based on data held by one of the authors but not all had direct access to the raw data. At the time of writing (2002/03), not all the original authors were given access to the raw data. In 2006, the American Association of Medical Colleges published recommendations regarding access to raw data (thttp://www.phrma.org/). These proposed that the sponsor may conduct all the analyses but that the investigators should be able to conduct their own analysis if they deem it to be necessary, and we endorse these recommendations. The original figures were based on all of the data available. However, the smoothing lines were cropped. In the redrawn figures, presented in this letter, there is no cropping of these lines. The authors used the term "threshold" in the original paper based on visual inspection of the figures and the statistical analysis of the bone resorption marker T-score and fracture risk; the latter showed that the relationship was best fit by including a quadratic term (in addition to a linear term). We have been able to confirm this finding in our reanalysis. We went on to divide bone resorption marker percent changes into deciles (Table 1 of the appendix) and we concluded for CTX (but not NTX) that there was a critical point after which no further decrease in vertebral fracture risk associated with further decreases in bone resorption markers. The critical value of this percent decrease was 51%. We divided bone resorption T-scores into deciles (Table 2 of the appendix), we went on to fit a Cox regression to the data, and we concluded that the decile approach supports the hypothesis that there is a threshold level for CTX T-scores (but not for NTX), below which a further reduction in bone resorption is not associated with a further reduction in fracture risk. The critical value of this T-score for CTX was 0. Clearly, this hypothesis needs testing in other studies, and the p value should be treated with caution because it was calculated posthoc. We stated three conclusions at the end of our paper.1 The first was "The baseline level of bone resorption is related to subsequent fracture risk." This conclusion can still be supported. The second was "The reduction in bone resorption explains, in part, the reduction in the risk of fractures with risedronate." This conclusion has been confirmed using the method of Li et al.4 The third conclusion was "There is a level of bone turnover reduction below w
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212
“In the VERT study [131], the fracture risk was at its lowest when the uCTX level was below a critical point that was equivalent to the mean value for premenopausal women.”
BackgroundSelf-citationUse of bone turnover markers in postmenopausal osteoporosis
Eastell, R., & Szulc, P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30184-5 · Cited by 594
Self-citationBisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease
Greenblatt, M. B., Tsai, J. N., & Wein, M. N. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.259085 · Cited by 376
Metadata
- Authors
- Eastell, R., Hannon, R. A., Garnero, P., Campbell, M. J., & Delmas, P. D.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-11-01
- Volume
- 22
- Issue
- 11
- Pages
- 1656-1660
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2026677867
- Cited by
- 76
- References
- 0
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis. https://app.cochat.ai/papers/10.1359/jbmr.07090b
- The paper
- Eastell, R., Hannon, R. A., Garnero, P., Campbell, M. J., & Delmas, P. D. (2007). Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.07090b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.